Medtronic
Medtronic plc, a global leader in medical technology, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 1949, the company has pioneered advancements in various medical fields, including cardiovascular, diabetes, and neurological care. Medtronic is renowned for its innovative core products, such as insulin pumps, cardiac devices, and surgical instruments, which are designed to improve patient outcomes and enhance quality of life. The company’s commitment to research and development has positioned it as a market leader, with notable achievements including the first successful implant of a cardiac pacemaker. With a strong focus on patient-centric solutions, Medtronic continues to set industry standards, making significant contributions to healthcare worldwide.
DitchCarbon Score
How does Medtronic's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Medtronic's score of 50 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Medtronic's reported carbon emissions
In 2023, Medtronic reported total greenhouse gas emissions of approximately 256,800,000 kg CO2e, comprising 131,500,000 kg CO2e from Scope 1 and 125,200,000 kg CO2e from Scope 2 emissions. The company has set ambitious targets to reduce its carbon footprint, committing to a 52% reduction in absolute Scope 1 and 2 emissions by 2030 from a 2020 baseline. Additionally, Medtronic aims to achieve 100% renewable electricity sourcing by 2030 and has set a target for 75% of its suppliers to have science-based targets by the same year. Medtronic is also focused on reducing its Scope 3 emissions, targeting a 37.5% reduction in emissions from upstream transportation and distribution, business travel, and end-of-life treatment of sold products by 2034, using a 2024 baseline. The company is committed to achieving net-zero emissions across all scopes by 2050, aligning with the Science Based Targets initiative (SBTi) standards. The emissions data and reduction targets are sourced from Medtronic plc, reflecting the company's commitment to sustainability and climate action within the healthcare equipment and supplies sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 74,992,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 |
| Scope 2 | 269,008,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Medtronic is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
